Discover
SLNO
Soleno Therapeutics, Inc.
53.01
2 x 38.15
2 x 67.82
bid
ask
+
0.00
0.00%
04:00 PM
timesize
| Ytd | 14.49% | |
| 1y | -29.33% |
52.98
day range
53.01
29.43
52 week range
90.32
| Open | 52.99 | Prev Close | 53.01 | Low | 52.98 | High | 53.01 | Mkt Cap | 2.76B |
| Vol | 0.00 | Avg Vol | 3.45M | EPS | 1.93 | P/E | 27.47 | Forward P/E | 13.12 |
| Beta | -2.22 | Short Ratio | 1.01 | Inst. Own | 111.53% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 45.78 | 200-d Avg | 51.16 | 1yr Est | 53.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-08-05 | 2026-06 | 0.91 | N/A | N/A | N/A |
| 2026-05-07 | 2026-03 | 0.73 | 0.59 | -0.14 | -19.18% |
| 2026-02-25 | 2025-12 | 0.64 | 0.8 | 0.16 | 25.00% |
| 2025-11-04 | 2025-09 | 0.06 | 0.47 | 0.41 | 717.39% |
| 2025-08-06 | 2025-06 | -0.53 | -0.09 | 0.44 | 83.02% |
| 2025-05-07 | 2025-03 | -1.14 | -0.95 | 0.19 | 16.67% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-04-17 | Wells Fargo | Downgrade | Overweight | Equal-Weight |
| 2026-04-08 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| 2026-04-07 | TD Cowen | Downgrade | Buy | Hold |
| 2026-04-07 | Wolfe Research | Downgrade | Outperform | Peer Perform |
| 2026-04-06 | Cantor Fitzgerald | Downgrade | Overweight | Neutral |
| 2026-03-18 | Oppenheimer | Upgrade | Outperform | Outperform |
Profile
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California. As of May 18, 2026, Soleno Therapeutics, Inc. operates as a subsidiary of Neurocrine Biosciences, Inc.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-01-20 | ANISH BHATNAGAR | Chief Executive Officer | 583.66K | Stock Award(Grant) |
| 2026-03-01 | FULK JENNIFER | Chief Financial Officer | 39.20K | Conversion of Exercise of derivative security |
| 2026-01-20 | HIRANO PATRICIA C | Officer | 22.70K | Stock Award(Grant) |
| 2026-03-26 | HUANG MICHAEL F | Officer | 39.82K | Sale |
| 2026-01-20 | JOSHI MANHER | Officer | 20.17K | Stock Award(Grant) |
| 2026-01-20 | MACKANESS JAMES H | Chief Financial Officer | 131.76K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | HHG PLC | 7.10M | 0.00 | 13.62% |
| 2026-03-30 | FMR Inc | 5.79M | 0.00 | 11.11% |
| 2026-03-30 | Wellington Management Company LLP | 4.43M | 0.00 | 8.49% |
| 2026-03-30 | BlackRock Inc | 3.74M | 0.00 | 7.18% |
| 2025-12-30 | Vanguard Group Inc | 3.06M | 0.00 | 5.87% |
| 2026-03-30 | State Street Corp | 2.68M | 0.00 | 5.14% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | Vanguard Health Care Inv | 3.01M | 0.00 | 5.78% |
| 2026-04-29 | Vanguard Total Stock Mkt Idx Inv | 1.56M | 0.00 | 3.00% |
| 2026-03-30 | Janus Henderson Global Life Sciences | 987.38K | 0.00 | 1.89% |
| 2026-03-30 | Janus Henderson Global Life Sciences D | 987.38K | 0.00 | 1.89% |
| 2026-03-30 | Janus Global Life Science AUSD | 910.95K | 0.00 | 1.75% |
| 2026-04-29 | International Biotechnology Ord | 648.53K | 0.00 | 1.24% |
Split
| Split | Date |
|---|---|
| 1 : 15 | 2022-08-26 |
| 1 : 5 | 2017-10-06 |